Bloomberg Intelligence Podcast: Live Nation Reaches DOJ Settlement in Antitrust Case

Date: March 9, 2026
Hosts: Paul Sweeney & Scarlet Fu
Featured Guests: Jennifer Ree (Bloomberg Intelligence), Deborah Aiken (Bloomberg Intelligence), Madison Mueller (Bloomberg News), Bess Friedman (Brown Harris Stevens)

Episode Overview

This episode centers on the DOJ's antitrust settlement with Live Nation, analyzing its implications for Ticketmaster, concertgoers, ticketing competitors, and the broader live entertainment landscape. The conversation extends to sector analyses, including pharmaceutical telehealth partnerships, luxury goods amid Middle East volatility, and the state of the U.S. housing market. Insights are provided by Bloomberg Intelligence analysts and industry experts.

Live Nation’s DOJ Settlement: Breaking Down the Case

(00:00–06:24)

What We Know So Far

• Jennifer Ree summarizes the live, evolving story of Live Nation's settlement with the DOJ:

  • The settlement includes a divestiture of large amphitheaters owned by Live Nation, opening the market to other promoters.

    “It looks like at least one part of it is a divestiture that would be divesting large amphitheaters that are owned by Live Nation… Artists really need [these venues] for summer tours, which was part of the problem.” – Jennifer Ree (02:10)

• DOJ alleged Live Nation owned 60 of the top 100 amphitheaters in the US—giving them a chokehold on a critical piece of the concert circuit.

Ticketmaster: Will It Be Broken Up?

• Key Issue:
  • The settlement does NOT force Live Nation to divest Ticketmaster.
  • 40 states are also plaintiffs—some, such as New York, reject the settlement as insufficient.
  • These states could pursue their own lawsuits to compel a Ticketmaster divestiture but face “long odds” without DOJ support:

    “Once you get the settlement with the Department of Justice and you lose the weight of the DOJ behind you on these antitrust matters, it is difficult for the states to go forward and win.” – Jennifer Ree (03:36)

• On prospective forced breakup:
  • “Even if [states] won a jury determination... I'm not so sure that the judge would be willing to stick his neck out and impose what's considered a really drastic remedy generally to force a company to break itself up.” – Jennifer Ree (03:44)

Will Concertgoers Notice a Difference?

• Host Nathan Hager raises the question of ticket prices and availability for everyday consumers:
  • “Does this DOJ settlement mean anything at all to you and me when we go out to try to buy tickets?... Man, you’re taking a small mortgage… Is that gonna get any better?” (04:00)
• Jennifer Ree remains skeptical:
  • “There are new terms here that they're talking about that again are behavioral… If Live Nation's been able to get around behavioral conditions since 2010, I'm not sure what's going to stop them now.” (04:23)
  • The case has rare bipartisan political momentum, with consumer dissatisfaction across the spectrum.

Ticketmaster’s Competitors: SeatGeek and the Market

• SeatGeek’s Experience:
  • SeatGeek, originally a secondary marketplace, has struggled to enter primary ticketing, which they attribute to Live Nation’s dominance.
  • “They say they have superior technology… but they haven’t been able to get those venues signed up because they’re either locked into long term exclusives with Ticketmaster, or because Live Nation… said, 'We won’t bring our artists to your venue if you use someone other than Ticketmaster.'” – Jennifer Ree (05:40)

Health Sector Focus: Novo Nordisk & Hims and Hers Settlement

(08:46–14:04)

A New Partnership from Legal Adversaries

• Madison Mueller recaps a surprising truce:
  • After months of legal feuding—including lawsuits over knockoff weight-loss drugs—Novo Nordisk and Hims and Hers are partnering again.
  • Novo will now sell discounted versions of its weight-loss medications through Hims and Hers’ telehealth platform.

Notable Quote:

“They are now pairing up for the second time to allow Novo to sell discounted versions of its weight loss drugs on Hims and hers' telehealth platform… This is definitely a surprise to, I think, a lot of investors.” – Madison Mueller (09:12)

Why the Detente?

• Regulatory Pressure:
  • Hims is under legal, FDA, and potential SEC investigations.
  • Novo is losing market share to telehealth platforms and to Eli Lilly.

Industry Trend:

• E-health/telehealth platforms (Hims, RO, Weight Watchers) are key to the rapid growth of weight-loss drugs.
• These partnerships provide convenience, lower cost, and direct access for patients.

Novo’s New CEO: A Hands-on Strategy

• Mike Dude Star is taking a more aggressive, hands-on approach than his predecessors:
  • “He was very involved… shepherded this renewed partnership between the two companies.” – Madison Mueller (12:41)
  • Novo is pushing further into consumer-facing platforms, improving digital experiences, and accelerating moves to regain market share in the lucrative US arena.

Luxury Sector Outlook: Middle East Conflict and Global Brands

(16:26–20:30)

Quantifying the Impact of Geopolitical Turmoil

• Deborah Aiken analyzes how the war in the Middle East is affecting luxury growth projections, particularly for 2026:
  • “The highest growth was set to come from Middle East at around 6%... If we see demand coming off in the Middle East locally at around 10%, that gave us about a 50bps dent for every 10% that was coming off.” – Deborah Aiken (17:12)

Key Insights:

• Luxury groups like LVMH, Hermes, and Richemont have significant exposure in the Middle East.
• “Overall, we would expect Rolexes and others to do very well with waiting lists. So high end jewelry and some of the high end leather goods or apparel makers would do very well.” – Deborah Aiken (18:29)
• Spirits, particularly cognac, face a less robust outlook (“growth outlook… wasn’t very strong” – 20:01).

U.S. Housing Market: Uncertainty, Inventory & Affordability

(22:52–29:41)

Effect of International Conflicts

• Bess Friedman (Brown Harris Stevens) outlines housing market implications:
  • “It’s just more volatility and uncertainty. And I think… we’ve already had… a frozen housing market and some challenges with affordability. And this just creates a bit more concern for buyers.” (23:28)

Is Cash Still King?

• “Last year we saw, you know, especially in places like New York City… cash is king. More than half the deals last year in NYC were done in cash.” – Bess Friedman (24:41)
• International buyers are less present; most movement is domestic.

Where’s the Value?

• “There are certain pockets… where there’s ample supply, but where you see tighter supply… buyers are much more challenged. Real estate is so local.” – Bess Friedman (25:51)

Existing Homes vs. New Construction

• Ongoing shortage of homes (~4 million deficit). Builders are cautious, and those with locked-in low rates are disincentivized from selling.
• Legislative efforts (“City of Yes”) aim to improve supply.

Mortgage Outlook & Affordability

• No immediate evidence of tighter lending, but affordability is a crisis.
• “First time homebuyers are now roughly 40 years old when they used to be 28 years old… People have been priced out of the American dream.” – Bess Friedman (28:34)
• The main issue remains constrained supply.

Notable Quotes & Memorable Moments

• “There are new terms here… but if Live Nation’s been able to get around behavioral conditions since 2010, I’m not sure what’s going to stop them now.” – Jennifer Ree (04:23)
• “Cash is king… More than half the deals last year in New York City were done in cash.” – Bess Friedman (24:41)
• “First time homebuyers are now roughly 40 years old when they used to be 28 years old…” – Bess Friedman (28:34)
• “The highest growth [in luxury] was set to come from the Middle East… If we see demand coming off… quickly we could see about 1.5% shaved off that 4% overall for the global industry.” – Deborah Aiken (17:12)

Timestamps for Key Segments

• DOJ–Live Nation Settlement & Ticketmaster: 01:54–06:24
• Telehealth & the Pharma Sector: Novo Nordisk and Hims and Hers: 08:46–14:04
• Luxury Goods & Middle East Geopolitical Effects: 16:26–20:30
• Residential Real Estate Market with Bess Friedman: 22:52–29:41

This comprehensive discussion connects ongoing antitrust litigation, changing business strategies in pharma, the resilience of luxury brands, and the persistent challenges in the U.S. housing market, offering investors and consumers critical insights into today’s most dynamic sectors.